

Date: December 17, 2013

To: North Zone, Central Zone and South Zone
Physicians, Nurse Managers, Educators and Practitioners, Laboratory Directors
and Managers

From: AHS Laboratory Services

Re: Meditech Biliary Atresia Order Entry Code

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Messages:

- On December 10, 2013 the laboratories in North, Central and South Zones introduced a new testing algorithm for Biliary Atresia risk on patients between the ages of 7 days and 5 months less one day. This resulted in a new test code created for Meditech order entry.
- The new test code for ordering quantitative bilirubin when a patient is ***between the ages of 7 days and 5 months less one day is BILN1***. This test code will ensure the automatic reflex testing will occur, if appropriate, for Biliary Atresia, including total or neonatal bilirubin, direct bilirubin and percent of direct bilirubin.
- The test codes **BILN** (neonatal bilirubin) and **BILT** (total bilirubin) remain active and are to be used for bilirubin testing for patients ***less than 7 days OR greater than or equal to 5 months of age, respectively***. If these codes are used for patients between the ages of 7 days and 5 months less one day, then you will be prompted to order the test code BILN1 and delete the incorrect test code ordered, e.g. BILT.

Action Required:

- Order **BILN1** in Meditech when bilirubin testing is required for patients ***between the ages of 7 days and 5 months less one day***.
- Order **BILN** (BILT if BILN not available) for bilirubin testing for patients ***less than 7 days of age***.
- Order **BILT** for bilirubin testing for patients ***greater than or equal to 5 months of age***.

Inquiries and feedback may be directed to:

- Your local laboratory
- Dr. Allison Venner, Clinical Biochemist, Central Zone at: 403-406-5633 or email: allison.venner@albertahealthservices.ca
- Karen Williams, Executive Director, Laboratory Quality, Safety and Integration at: 780-342-8487 or email: karen.e.williams@albertahealthservices.ca

This bulletin has been reviewed and approved by:
Dr. James Wesenberg, Provincial Medical / Scientific Director, AHS Laboratory Services